Logo image of ALDX

ALDEYRA THERAPEUTICS INC (ALDX) Stock Fundamental Analysis

NASDAQ:ALDX - Nasdaq - US01438T1060 - Common Stock - Currency: USD

2.78  -0.15 (-5.12%)

Premarket: 2.78 0 (0%)

Fundamental Rating

1

ALDX gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 557 industry peers in the Biotechnology industry. ALDX has a bad profitability rating. Also its financial health evaluation is rather negative. ALDX does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year ALDX has reported negative net income.
In the past year ALDX has reported a negative cash flow from operations.
ALDX had negative earnings in each of the past 5 years.
ALDX had a negative operating cash flow in each of the past 5 years.
ALDX Yearly Net Income VS EBIT VS OCF VS FCFALDX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M

1.2 Ratios

ALDX has a Return On Assets of -61.91%. This is in the lower half of the industry: ALDX underperforms 60.32% of its industry peers.
ALDX has a Return On Equity (-90.72%) which is in line with its industry peers.
Industry RankSector Rank
ROA -61.91%
ROE -90.72%
ROIC N/A
ROA(3y)-37.64%
ROA(5y)-36.54%
ROE(3y)-50.36%
ROE(5y)-48.45%
ROIC(3y)N/A
ROIC(5y)N/A
ALDX Yearly ROA, ROE, ROICALDX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80 -100

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ALDX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ALDX Yearly Profit, Operating, Gross MarginsALDX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

3

2. Health

2.1 Basic Checks

The number of shares outstanding for ALDX has been increased compared to 1 year ago.
The number of shares outstanding for ALDX has been increased compared to 5 years ago.
Compared to 1 year ago, ALDX has a worse debt to assets ratio.
ALDX Yearly Shares OutstandingALDX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
ALDX Yearly Total Debt VS Total AssetsALDX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

Based on the Altman-Z score of -4.69, we must say that ALDX is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -4.69, ALDX perfoms like the industry average, outperforming 41.83% of the companies in the same industry.
A Debt/Equity ratio of 0.24 indicates that ALDX is not too dependend on debt financing.
ALDX has a Debt to Equity ratio of 0.24. This is in the lower half of the industry: ALDX underperforms 71.10% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.24
Debt/FCF N/A
Altman-Z -4.69
ROIC/WACCN/A
WACCN/A
ALDX Yearly LT Debt VS Equity VS FCFALDX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M 150M 200M

2.3 Liquidity

ALDX has a Current Ratio of 6.49. This indicates that ALDX is financially healthy and has no problem in meeting its short term obligations.
ALDX has a Current ratio of 6.49. This is in the better half of the industry: ALDX outperforms 63.38% of its industry peers.
A Quick Ratio of 6.49 indicates that ALDX has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 6.49, ALDX is in the better half of the industry, outperforming 63.73% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 6.49
Quick Ratio 6.49
ALDX Yearly Current Assets VS Current LiabilitesALDX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

More info and screens

1

3. Growth

3.1 Past

The earnings per share for ALDX have decreased strongly by -90.20% in the last year.
EPS 1Y (TTM)-90.2%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-21.43%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 26.14% on average over the next years. This is a very strong growth
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y14.74%
EPS Next 2Y12.18%
EPS Next 3Y28.34%
EPS Next 5Y26.14%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ALDX Yearly Revenue VS EstimatesALDX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2023 2025 2026 2027 2028 2029 2030 2031 2032 50M 100M 150M 200M 250M
ALDX Yearly EPS VS EstimatesALDX Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 1 -1 -2

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

ALDX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year ALDX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ALDX Price Earnings VS Forward Price EarningsALDX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ALDX Per share dataALDX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1

4.3 Compensation for Growth

A more expensive valuation may be justified as ALDX's earnings are expected to grow with 28.34% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y12.18%
EPS Next 3Y28.34%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ALDX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ALDEYRA THERAPEUTICS INC

NASDAQ:ALDX (6/13/2025, 8:00:00 PM)

Premarket: 2.78 0 (0%)

2.78

-0.15 (-5.12%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-14 2025-05-14/amc
Earnings (Next)07-30 2025-07-30
Inst Owners48%
Inst Owner Change2.95%
Ins Owners2.98%
Ins Owner Change0%
Market Cap166.52M
Analysts87.69
Price Target8.45 (203.96%)
Short Float %8.94%
Short Ratio2.27
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)11.48%
Min EPS beat(2)-17.52%
Max EPS beat(2)40.48%
EPS beat(4)2
Avg EPS beat(4)-17.48%
Min EPS beat(4)-93.66%
Max EPS beat(4)40.48%
EPS beat(8)5
Avg EPS beat(8)5.65%
EPS beat(12)9
Avg EPS beat(12)9.97%
EPS beat(16)11
Avg EPS beat(16)7.59%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-19.44%
EPS NQ rev (1m)-85.92%
EPS NQ rev (3m)-89.97%
EPS NY rev (1m)0%
EPS NY rev (3m)-72.04%
Revenue NQ rev (1m)-101.11%
Revenue NQ rev (3m)-100.85%
Revenue NY rev (1m)0%
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 2.62
P/tB 2.62
EV/EBITDA N/A
EPS(TTM)-0.97
EYN/A
EPS(NY)-0.7
Fwd EYN/A
FCF(TTM)-0.76
FCFYN/A
OCF(TTM)-0.76
OCFYN/A
SpS0
BVpS1.06
TBVpS1.06
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -61.91%
ROE -90.72%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-37.64%
ROA(5y)-36.54%
ROE(3y)-50.36%
ROE(5y)-48.45%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.24
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.49
Quick Ratio 6.49
Altman-Z -4.69
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-90.2%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-21.43%
EPS Next Y14.74%
EPS Next 2Y12.18%
EPS Next 3Y28.34%
EPS Next 5Y26.14%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-72.83%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year8.9%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y14.1%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y14.1%
OCF growth 3YN/A
OCF growth 5YN/A